Pembrolizumab and FOLFOX-6 Modified Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Pembrolizumab and FOLFOX-6 Modified Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/839-pembrolizumab-and-folfox-6-modified-therapy.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	HER2-negative, PD-L1 (CPS) >= 10	Adenocarcinoma of the Gastroesophageal Junction	Fluorouracil, Oxaliplatin, Pembrolizumab